Peter Wehrwein, Managing Editor

Session on diabetic retinopathy includes results from trials of a variety of approaches to retinopathy.

Findings from an analysis of data from the pivotal PHOTON trial didn't show any increased risk of higher intraocular pressure building from injections of the high-dose, 8-mg version of Eylea.

But the presenter downplayed the rivalry between the two new treatments for geographic atrophy. “I think we are lucky to have multiple therapies,” saidPaul Hahn, M.D., Ph.D. of NJRetina.

In this part two interview with Parisi Emami-Naeini from UC Davis Eye Center, she explains that improvements in methods and instruments, faster procedure time and declining reimbursement rates have made pars plana vitrectomy the preferred method for repairing detached retinas, along with reduced training in scleral buckle procedures for new retina specialists.

The study's results were presented today at the American Society of Retina Specialists meeting in Stockholm, Sweden, by Parisi Emami-Naeini, M.D., M.P.H., a retina specialist at the Tschannen Eye Institute at the UC Davis Eye Center.

But the Mayo Clinic ophthalmologist who presented the findings stressed that it was “hugely reassuring” the GLP-1s were comparable to older diabetes drugs with respect to retinopathy given all their other advantages.

Emerson, the program chair of ASRS and one of the organizers of the meeting's content, is a retina specialist at Retina Consultants of Minnesota and medical director at the Phillips Eye Institute in Minneapolis and an associate adjunct professor at the University of Minnesota.

Geoffrey G. Emerson of Retina Consultants of Minnesota and medical director at the Phillips Eye Institute in Minneapolis and an associate adjunct professor at the University of Minnesota, previews the 2024 annual meeting of the American Society of Retina Specialists (ASRS) starting Wednesday, July 17, in Stockholm, Sweden.

One theme of the Federal Trade Commission’s interim take on pharmacy benefit managers is vertical integration and how that affects competition in the industry.

The active ingredient in Ozempic and Wegovy is linked to nonarteritic anterior ischemic optic neuropathy (NAION), the second most common form of optic neuropathy. This is apparently the first study to link semaglutide to the eye condition.

The presidential candidates didn't spend a lot of time talking about healthcare issues last night, but Democrats are concerned about Biden's performance, especially early on.

Lack of standardization has obscured complication rates in clinical trials, say a team of researchers. In results reported in the journal Ophthalmology earlier month, they list 67 ocular complications that experts agreed upon using a Delphi process,

The CMS released its projections earlier this month, saying healthcare spending will hit $7.7 trillion by 2032.

The newspaper’s investigation, which included interviewing 300 peole, found that pharmacy benefit manager often act in their own financial interest by overcharging employers and government programs.

Experts on AI spoke about strategies and tactics for implementing artificial intelligence that would assuage worries and build trust during a keynote session at AHIP annual meeting.

Researchers say their findings of increased prevalence argue for screening for diabetic retinopathy in young adults.

Congressional Budget Office analysts say that Medicaid unwinding, immigration and scheduled end of ACA premium subsidies are factors in the increase.

Even though value-based care has been talked about for a long time, it may not be the end.

In 2024, there have been two common health plan issues brought up by employers.

Harvard researcher Zirui Songsays research findings show that nospitals higher prices and lower quality.

Three speakers, three different takes on the state of U.S. healthcare and what ails it.

In an interview prior to the AHIP 2024 conference in Las Vegas, MHE spoke with Sachin H. Jain, M.D.,MBA, CEO, SCAN Group and SCAN Health Plan, who acknowledged that while SCAN isn't perfect, they are ahead in simplifying healthcare by recognizing their role in the problem.

In an interview prior to the AHIP 2024 conference in Las Vegas, MHE spoke with Sachin H. Jain, M.D.,MBA, CEO, SCAN Group and SCAN Health Plan, about the need to reimagine U.S. healthcare, emphasizing a leadership crisis.

CDC Director Mandy K. Cohen spabout the agency modernizing data and working with payers and other parts of the healthcare system at the AHIP meeting in Las Vegas.

Merith Basey, executive director of Patients for Affordable Drug, talks about strategies for lowering the cost of new drugs, especially cell and gene therapy, in a second part of a video interview conducted prior to the June 11-13 AHIP 2024 meeting in Las Vegas.

Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies, in an interview with MHE previewing the presentation she's co-presenting on June 11 at the AHIP 2024 meeting in Las Vegas.

In the latest episode of the Meet the Board podcast series, Managing Editor, Peter Wehrwein, catches up with Chief Clinical Officer at Optum Rx and EAB member, David Calabrese, about his new role alongside his team's progress in improving quality, patient safety and health equity in healthcare.

A growing proportion of small- and medium-sized employers are self-insuring. But with self-insurance, comes fiduciary responsibility and possible scrutiny.

Some large randomized trials have suggested that taking low doses of aspirin on a daily basis would be an easy, inexpensive way of lowering the risk of getting age-related macular degeneration. Not so a well-designed, placebo-controlled study of septuagenarians conducted in Australia.